{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:51:47Z","timestamp":1794664307065,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11704-w","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:08:27Z","timestamp":1761300507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Parasite clearance of two commonly administered artemisinin-based combination therapies in under-five children with uncomplicated malaria in a comprehensive healthcare facility in South-Western Nigeria: a randomised controlled trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8514-0587","authenticated-orcid":false,"given":"Abdulakeem Ayanleye","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5326-2894","authenticated-orcid":false,"given":"Ibrahim Sebutu","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitayo Oluwatoyin","family":"Adewole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-6753","authenticated-orcid":false,"given":"Samuel Anu","family":"Olowookere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olanrewaju Oloyede","family":"Oyegbade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-782X","authenticated-orcid":false,"given":"Akinjide Olurotimi","family":"Ogundokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-0723","authenticated-orcid":false,"given":"Temitope Oluwafemi","family":"Olajubu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-3861","authenticated-orcid":false,"given":"Roland I.","family":"Funwei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusola","family":"Ojurongbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7561-510X","authenticated-orcid":false,"given":"Daniel Adeife","family":"Adepoju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2120-1231","authenticated-orcid":false,"given":"Abdulhakeem Bolaji","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulwasiu Akanfe","family":"Adegboyega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atinuke Olu","family":"Anjorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Olushola","family":"Anjorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olubunmi Olateju","family":"Akinola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4439-1362","authenticated-orcid":false,"given":"Kolawole Muideen","family":"Adewumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Kelechi","family":"Omenugha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8989-2863","authenticated-orcid":false,"given":"Oluwasina Tajudeen","family":"Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-1480","authenticated-orcid":false,"given":"Akintayo Olayinka","family":"Familusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Oluwatimilehin","family":"Akande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"11704_CR1","volume-title":"WHO guidelines for malaria","author":"World Health Organisation","year":"2021","unstructured":"World Health Organisation. WHO guidelines for malaria. Geneva: World Health Organisation; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"1","key":"11704_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-89295-0","volume":"11","author":"S Das","year":"2021","unstructured":"Das S, Kar A, Manna S, Mandal S, Mandal S, Das S, et al. Artemisinin combination therapy fails even in the absence of plasmodium falciparum kelch13 gene polymorphism in central India. Sci Rep. 2021;11(1):1\u201312.","journal-title":"Sci Rep"},{"issue":"4","key":"11704_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3201\/eid2304.161872","volume":"23","author":"BQ Phuc","year":"2017","unstructured":"Phuc BQ, Rasmussen C, Duong TT, Loi MA, M\u00e9nard D, Tarning J, et al. Treatment failure of dihydroartemisinin\/piperaquine for plasmodium falciparum malaria, Vietnam. Emerg Infect Dis. 2017;23(4):715.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"11704_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin\u2013piperaquine resistance in plasmodium falciparum malaria in cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16(3):357\u201365.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"11704_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/trstmh\/trz009","volume":"113","author":"A Uwimana","year":"2019","unstructured":"Uwimana A, Penkunas MJ, Nisingizwe MP, Warsame M, Umulisa N, Uyizeye D, et al. Efficacy of Artemether\u2013Lumefantrine versus Dihydroartemisinin\u2013Piperaquine for the treatment of uncomplicated malaria among children in rwanda: an Open-Label, randomised controlled trial. Trans R Soc Trop Med Hyg. 2019;113(6):312\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"11704_CR6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2022","unstructured":"Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with Artemether-Lumefantrine. J Infect Dis. 2022;225(8):1411\u20134.","journal-title":"J Infect Dis"},{"issue":"4","key":"11704_CR7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3201\/eid2404.170141","volume":"24","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Kaneko M, Tachibana S-I, Balikagala B, Sakurai-Yatsushiro M, Yatsushiro S, et al. Artemisinin-resistant plasmodium falciparum with high survival rates, Uganda, 2014\u20132016. Emerg Infect Dis. 2018;24(4):718.","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"11704_CR8","doi-asserted-by":"publisher","first-page":"e26005","DOI":"10.1371\/journal.pone.0026005","volume":"6","author":"S Borrmann","year":"2011","unstructured":"Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining responsiveness of plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan Coast. PLoS ONE. 2011;6(11):e26005. https:\/\/doi.org\/10.1371\/journal.pone.0026005.","journal-title":"PLoS ONE"},{"key":"11704_CR9","doi-asserted-by":"publisher","unstructured":"Mukhongo HN, Kinyua JKe, Weldemichael YG, Kasili RW. Screening for antifolate and Artemisinin resistance in plasmodium falciparum clinical isolates from three hospitals of Eritrea. F1000 research. 2023;10:628. https:\/\/doi.org\/10.12688\/f1000research.54195.2","DOI":"10.12688\/f1000research.54195.2"},{"issue":"1","key":"11704_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansan\u00e9","year":"2021","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-Malarial efficacy and resistance monitoring of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20(1):48\u201359.","journal-title":"Malar J"},{"issue":"2","key":"11704_CR11","first-page":"1","volume":"21","author":"GS Wundermann","year":"2017","unstructured":"Wundermann GS, Osiki AA. Currently observed trend in the resistance of malaria to Artemisinin-Based combination therapy in Nigeria \u2013 A report of 5 cases. Infect Drug Resist. 2017;21(2):1\u20135.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"11704_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1590\/0037-8682-0098-2013","volume":"46","author":"NA Ajayi","year":"2013","unstructured":"Ajayi NA, Ukwaja KN. Possible Artemisinin-Based combination Therapy-Resistant malaria in nigeria: A report of three cases. Rev Soc Bras Med Trop. 2013;46(4):525\u20137.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"11704_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jgar.2021.09.001","volume":"27","author":"N Noreen","year":"2021","unstructured":"Noreen N, Ullah A, Salman SM, Mabkhot Y, Alsayari A, Badshah SL. New insights into the spread of resistance to Artemisinin and its analogues. J Glob Antimicrob Resist. 2021;27(3):142\u20139.","journal-title":"J Glob Antimicrob Resist"},{"issue":"10","key":"11704_CR14","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JL, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602\u20138. doi.org\/10.038\/s41591-020-1005-2.","journal-title":"Nat Med"},{"issue":"2","key":"11704_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.60787\/tnhj.v23i2.670","volume":"23","author":"AA Iwuafor","year":"2023","unstructured":"Iwuafor AA, Ogban GI, Elem DE, Emanghe UE, Owai PA, Erengwa PC, et al. Plasmodium falciparum Kelch 13-propeller gene mutation update in Nigeria \u2013 a systematic review. Nigerian Health J. 2023;23(2):587\u201396. https:\/\/doi.org\/10.60787\/tnhj.v23i2.670.","journal-title":"Nigerian Health J"},{"issue":"7","key":"11704_CR16","doi-asserted-by":"publisher","first-page":"25333205","DOI":"10.1101\/2025.08.07","volume":"8","author":"JM Ndong Ngomo","year":"2025","unstructured":"Ndong Ngomo JM, Mawili-Mboumba DP, Mouity TN, Leonetti A, Mabika DM, Mihindou JC. Clonal Transmission of Emerging Novel Plasmodium falciparum Kelch13 Mutations and Increasing Complexity of Infection in Libreville, Gabon, 2021\u20132023. medRxiv. 2025;8(7):25333205. https:\/\/doi.org\/10.1101\/2025.08.07. medRxiv.","journal-title":"medRxiv"},{"issue":"8","key":"11704_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm.4381","volume":"23","author":"B Blasco","year":"2017","unstructured":"Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23(8):917\u201328.","journal-title":"Nat Med"},{"issue":"2","key":"11704_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/trstmh\/trx019","volume":"111","author":"O Izevbekhai","year":"2017","unstructured":"Izevbekhai O, Adeagbo B, Olagunju A, Bolaji O. Quality of artemisinin-based antimalarial drugs marketed in Nigeria. Trans R Soc Trop. 2017;111(2):90\u20136.","journal-title":"Trans R Soc Trop"},{"key":"11704_CR19","first-page":"1","volume-title":"National bureau of statistics (NBS), and ICF International. Nigeria malaria indicator survey 2021 final Report. Abuja, Nigeria, and Rockville","author":"National Malaria Elimination Programme (NMEP) NPCN","year":"2022","unstructured":"National Malaria Elimination Programme (NMEP) NPCN. National bureau of statistics (NBS), and ICF International. Nigeria malaria indicator survey 2021 final Report. Abuja, Nigeria, and Rockville. Maryland, USA: NMEP, NPopC, and ICF International; 2022. pp. 1\u2013190."},{"key":"11704_CR20","unstructured":"Federal Ministry of Health NMCP, Abuja, Nigeria. Nigeria Strategic Plan 2009\u20132013. 2009.https:\/\/extranet.who.int\/countryplanningcycles\/sites\/default\/files\/planning_cycle_repository\/nigeria\/nigeria_draft_malaria_strategic_plan_2009-13.pdf"},{"key":"11704_CR21","volume-title":"National guideline for diagnosis and treatment of malaria","author":"Federal Ministry of Health, Nigeria","year":"2020","unstructured":"Federal Ministry of Health, Nigeria. National guideline for diagnosis and treatment of malaria. 4th ed. Abuja, Nigeria: National Malaria Elimination Programme; 2020.","edition":"4"},{"issue":"1","key":"11704_CR22","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.2147\/IDR.S167518","volume":"11","author":"OA Toure","year":"2018","unstructured":"Toure OA, Landry TNG, Assi SB, Kone AA, Gbessi EA, Ako BA, et al. Malaria parasite clearance from patients following Artemisinin-Based combination therapy in C\u00f4te d\u2019ivoire. Infect Drug Resist. 2018;11(1):2031\u201338.","journal-title":"Infect Drug Resist"},{"key":"11704_CR23","first-page":"1","volume-title":"Artemisinin resistance and Artemisinin-Based combination therapy efficacy","author":"World Health Organisation","year":"2018","unstructured":"World Health Organisation. Artemisinin resistance and Artemisinin-Based combination therapy efficacy. Geneva: World Health Organisation; 2018. pp. 1\u201310."},{"key":"11704_CR24","unstructured":"WHO. | Responding to antimalarial drug resistance. WHO. 2018."},{"key":"11704_CR25","unstructured":"World Health Organisation. Methods for Surveillance of Antimalarial Drug Efficacy. Geneva: World Health Organisation. 2009. Available from: https:\/\/www.who.int\/docs\/default-source\/documents\/publications\/gmp\/methods-for-surveillance-of-antimalarial-drug-efficacy.pdf?sfvrsn=29076702_2"},{"issue":"3","key":"11704_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.4269\/ajtmh.18-0115","volume":"99","author":"JC Ebenebe","year":"2018","unstructured":"Ebenebe JC, Ntadom G, Ambe J, Wammanda R, Jiya N, Finomo F, et al. Efficacy of Artemisinin-Based combination treatments of uncomplicated falciparum malaria in Under-Five-Year-Old Nigerian children ten years following adoption as First-Line antimalarials. Am J Trop Med Hyg. 2018;99(3):649\u201364.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"11704_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1475-2875-13-243","volume":"13","author":"CC Ezenduka","year":"2014","unstructured":"Ezenduka CC, Ogbonna BO, Ekwunife OI, Okonta MJ, Esimone CO. Drugs use pattern for uncomplicated malaria in medicine retail outlets in Enugu Urban, Southeast nigeria: implications for malaria treatment policy. Malar J. 2014;13(1):243\u201353.","journal-title":"Malar J"},{"issue":"1","key":"11704_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/1475-2875-12-254","volume":"12","author":"A Agarwal","year":"2013","unstructured":"Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, et al. A randomised trial of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in the treatment of uncomplicated malaria among children in Western Kenya. Malar J. 2013;12(1):254\u201361.","journal-title":"Malar J"},{"key":"11704_CR29","unstructured":"World Health Organisation. World malaria report 2024: addressing inequity in the global malaria response. Geneva: World Health Organisation. 2024. p. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"5","key":"11704_CR30","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/ndt\/gfp732","volume":"25","author":"M Noordzij","year":"2010","unstructured":"Noordzij M, Tripepi G, Dekker FW, Zoccali C, Tanck MW, Jager KJ. Sample size calculations: basic principles and common pitfalls. Nephrol Dialysis Transpl. 2010;25(5):1388\u201393.","journal-title":"Nephrol Dialysis Transpl"},{"issue":"1","key":"11704_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12936-014-0521-2","volume":"14","author":"AM Nji","year":"2015","unstructured":"Nji AM, Ali IM, Moyeh MN, Ngongang EO, Ekollo AM, Chedjou JP, et al. Randomised Non-inferiority and safety trial of Dihydroartemisin-Piperaquine and Artesunate-Amodiaquine versus Artemether-Lumefantrine in the treatment of uncomplicated plasmodium falciparum malaria in Cameroonian children. Malar J. 2015;14(1):27\u201336.","journal-title":"Malar J"},{"issue":"2","key":"11704_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.vaccine.2015.11.018","volume":"34","author":"MS Gold","year":"2016","unstructured":"Gold MS, Balakrishnan MR, Amarasinghe A, MacDonald NE. An approach to death as an adverse event following immunisation. Vaccine. 2016;34(2):212\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"11704_CR33","first-page":"34","volume":"14","author":"B Zani","year":"2014","unstructured":"Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-Piperaquine for treating uncomplicated plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;14(1):34\u201342.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"11704_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-017-2149-5","volume":"17","author":"RI Funwei","year":"2018","unstructured":"Funwei RI, Thomas BN, Falade CO, Ojurongbe O. Extensive diversity in the allelic frequency of plasmodium falciparum merozoite surface proteins and Glutamate-Rich protein in rural and urban settings of Southwestern Nigeria. Malar J. 2018;17(1):1\u20138.","journal-title":"Malar J"},{"key":"11704_CR35","volume-title":"Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas: report of a virtual meeting, 17\u201318 May 2021","author":"World Health Organisation","year":"2021","unstructured":"World Health Organisation. Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas: report of a virtual meeting, 17\u201318 May 2021. Geneva: World Health Organisation; 2021."},{"issue":"5","key":"11704_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.pt.2020.02.005","volume":"36","author":"DS Khoury","year":"2020","unstructured":"Khoury DS, Zaloumis SG, Grigg MJ, Haque A, Davenport MP. Malaria parasite clearance: what are we really measuring? Trends Parasitol. 2020;36(5):413\u201326.","journal-title":"Trends Parasitol"},{"issue":"12","key":"11704_CR37","doi-asserted-by":"publisher","first-page":"7049","DOI":"10.1128\/AAC.02746-14","volume":"58","author":"K Thriemer","year":"2014","unstructured":"Thriemer K, Hong NV, Rosanas-Urgell A, Phuc BQ, Ha DM, Pockele E, et al. Delayed parasite clearance after treatment with Dihydroartemisinin-Piperaquine in plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014;58(12):7049\u201355.","journal-title":"Antimicrob Agents Chemother"},{"key":"11704_CR38","unstructured":"World Health Organisation. Tools for Monitoring Antimalarial Drug Efficacy: WHO Data Entry and Analysis Tool 2017. Geneva: World Health Organisation. 2018. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/case-management\/drug-efficacy-and-resistance\/tools-for-monitoring-antimalarial-drug-efficacy"},{"issue":"3","key":"11704_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/2229-3485.184823","volume":"7","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Pramesh C, Aggarwal R. Common pitfalls in statistical analysis: Intention-to-Treat versus Per-Protocol analysis. Perspect Clin Res. 2016;7(3):144\u20136.","journal-title":"Perspect Clin Res"},{"key":"11704_CR40","first-page":"1","volume-title":"National guidelines for diagnosis and treatment of malaria","author":"Federal Ministry of Health","year":"2015","unstructured":"Federal Ministry of Health. National guidelines for diagnosis and treatment of malaria. 3rd ed. Abuja: National Malaria Elimination Programme; 2015. pp. 1\u201363.","edition":"3"},{"issue":"24","key":"11704_CR41","first-page":"1","volume":"25","author":"M Ouji","year":"2018","unstructured":"Ouji M, Augereau JM, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to Artemisinin-Based combination therapies: A sword of Damocles in the path toward malaria Elimination. Parasite. Parasite. 2018;25(24):1\u201312.","journal-title":"Parasite"},{"key":"11704_CR42","unstructured":"World Health Organisation. Q & A on Artemisinin Resistance. Geneva: World Health Organisation. 2019. Available from: https:\/\/www.who.int\/docs\/default-source\/malaria\/mpac-documentation\/mpac-april2018-q-a-artemisinin-resistance-session2.pdf?sfvrsn=ed1d4c78_2"},{"issue":"12","key":"11704_CR43","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3855\/jidc.3058","volume":"7","author":"O Ojurongbe","year":"2013","unstructured":"Ojurongbe O, Lawal OA, Abiodun OO, Okeniyi JA, Oyeniyi AJ, Oyelami OA. Efficacy of Artemisinin combination therapy for the treatment of uncomplicated falciparum malaria in Nigerian children. J Infect Dev Ctries. 2013;7(12):975\u201382.","journal-title":"J Infect Dev Ctries"},{"issue":"5","key":"11704_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.11648\/j.ajbls.20210905.16","volume":"9","author":"MH Ta\u00efsso","year":"2021","unstructured":"Ta\u00efsso MH, Souleymane IM, Alio HM, Diar MSI, Sougoudi DA, Mbanga D, et al. Effectiveness and tolerability of the ASAQ versus AL association in children 6\u201359 months for the treatment of uncomplicated P. falciparum malaria in Massakory (Chad). Am J Biomed Life Sci. 2021;9(5):259\u201366.","journal-title":"Am J Biomed Life Sci"},{"issue":"1","key":"11704_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-13-598","volume":"13","author":"K Sylla","year":"2013","unstructured":"Sylla K, Abiola A, Tine RCK, Faye B, Sow D, Ndiaye JL, et al. Monitoring the efficacy and safety of three Artemisinin-Based combination therapies in senegal: results from two years of surveillance. BMC Infect Dis. 2013;13(1):1\u201310.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"11704_CR46","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4269\/ajtmh.13-0248","volume":"91","author":"S Oguche","year":"2014","unstructured":"Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, et al. Efficacy of Artemisinin-Based combination treatments of uncomplicated falciparum malaria in Under-Five-Year-Old Nigerian children. Am J Trop Med Hyg. 2014;91(5):925\u201335.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"11704_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s40249-018-0503-7","volume":"7","author":"K Akano","year":"2018","unstructured":"Akano K, Ntadom G, Agomo C, Happi CT, Folarin OA, Gbotosho GO, et al. Parasite reduction ratio one day after initiation of Artemisinin-Based combination therapies and its relationship with parasite clearance time in acutely malarious children. Infect Dis Poverty. 2018;7(1):122\u201335.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"11704_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06018-6","volume":"21","author":"W Shibeshi","year":"2021","unstructured":"Shibeshi W, Alemkere G, Mulu A, Engidawork E. Efficacy and safety of Artemisinin-Based combination therapies for the treatment of uncomplicated malaria in paediatrics. BMC Infect Dis. 2021;21(1):1\u201312.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"11704_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12936-021-03760-9","volume":"20","author":"Y Diarra","year":"2021","unstructured":"Diarra Y, Kone O, Sangar\u00e9 L, Doumbia L, Haidara DB, Diallo M, et al. Therapeutic efficacy of Artemether\u2013Lumefantrine and Artesunate\u2013Amodiaquine for the treatment of uncomplicated plasmodium falciparum malaria in Mali, 2015\u20132016. Malar J. 2021;20(1):235\u201347.","journal-title":"Malar J"},{"issue":"1","key":"11704_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12936-015-1075-7","volume":"15","author":"HC Slater","year":"2016","unstructured":"Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of Artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016;15(1):10\u201321.","journal-title":"Malar J"},{"issue":"1","key":"11704_CR51","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1475-2875-12-250","volume":"12","author":"B Schramm","year":"2013","unstructured":"Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Tolerability and safety of Artesunate-Amodiaquine and Artemether-Lumefantrine fixed dose combinations for the treatment of uncomplicated plasmodium falciparum malaria: two Open-Label, randomised trials in Nimba County, Liberia. Malar J. 2013;12(1):250\u201362.","journal-title":"Malar J"},{"issue":"784","key":"11704_CR52","first-page":"1","volume":"11","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhang Z, Yu W, Lu C, Li G, Pan Z, et al. Surveillance of the efficacy of Artemisinin\u2013Piperaquine in the treatment of uncomplicated plasmodium falciparum malaria among children under 5 years of age in Est-Mono District, Togo, in 2017. Front Pharmacol. 2020;11(784):1\u20139.","journal-title":"Front Pharmacol"},{"issue":"1","key":"11704_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12936-019-2864-1","volume":"18","author":"M Warsame","year":"2019","unstructured":"Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM, et al. High therapeutic efficacy of Artemether\u2013Lumefantrine and Dihydroartemisinin\u2013Piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar J. 2019;18(1):231\u201341.","journal-title":"Malar J"},{"issue":"1","key":"11704_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12936-016-1099-7","volume":"15","author":"A Adjei","year":"2016","unstructured":"Adjei A, Narh-Bana S, Amu A, Kukula V, Owusu-Agyei S, Oduro A, et al. Outcomes in a safety observational study of Dihydroartemisinin\/Piperaquine (Eurartesim\u00ae) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J. 2016;15(1):43\u201352.","journal-title":"Malar J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11704-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T11:03:13Z","timestamp":1761303793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11704-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11704"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11704-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki. Ethical approval for the conduct of the study was obtained from the Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife Ethical Review Committee (ERC\/2019\/10\/06) (S1 File). The study was registered on 10\/07\/2020 with the Pan African Clinical Trials Registry, Cochrane South Africa (PACTR202007553348930) (S2 File). Written informed consent was obtained from the parents or guardians of eligible participants before their recruitment into the study. For the parents or guardians who could not read, the Subject Information Sheet was read and explained to them, and they thumb-printed their consent afterwards. Data were collected anonymously. All the caregiver-child pairs received a token of $1.5 to cover the costs of transportation and a light snack for each appointment at the comprehensive health centre. There were no changes to the pre-specified primary or secondary trial outcomes, nor were there any substantial amendments to the study protocol after the trial\u2019s initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the parents or legal guardians of the children.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1403"}}